Ensysce Biosciences UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Right. Come so many years.
Good day, everybody. Welcome back to UBS Global Biopharma Conference in London. Our next session, Ensysce Biosciences, very, very excited to learn about the story. We have the whole team, so thank you so much for joining, and my name is Ash from UBS with Cap Biotech and Spec Pharma. But would love to hear the story out, James, Richard, Roger, and Paul. I know we have some slides to go through, and then we can get into some Q&A after that.
Perfect. Yeah. Thank you for having us.
Have we got the- Yeah need the clicker.
If we're sitting here. There we go.
Oh, this is coming off.
We're now scrolling through the- I see.
Could we have our first slide, please?
Oh, it's actually coming. It's not showing down here.
Oh, it's not showing. but it is showing up there.
In that case, I will go to the lectern to start things off.
Yep. So we can actually see.
No, that is not our- There it is.
There we go. Fine. So, thank you very much. We are going to be talking about our neuroplastogenic therapies, and we will explain about psychedelics and bringing resilience and motivation to our, hopefully in the future, to many patients suffering from severe chronic pain. To set the scene for you, I am going to pass over initially to Roger to tell you about the business and commercial side of things.
Terrific. Thank you, Richard. Very quickly, we are a new company, in the sense that we just did a reverse merger, actually with Ensysce Biosciences. This is Cy Biopharma, and as Richard said, we are focused on the psychedelics space and using psychedelics for neuropathic pain syndromes. The transaction, the reverse merger was closed in August of this year. We were fortunate to raise a $77 million PIPE alongside that with some leading investors, including Perceptive, Ally Bridge Group, Dellora Investments, Ikarian Capital, and Adage. So we are excited about our investors and new investors coming aboard as well. We will be using that cash, obviously, to conduct clinical trials for our lead project in CRPS, as well as to drive novel therapeutics, novel ergolines for additional indications. We will talk about all of that in discussion today.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
